In a large study of adults with implanted heart devices that detected short, symptomless bouts of irregular heart rhythm, known as subclinical atrial fibrillation, those who took the anti-clotting ...

A new type of anti-clotting drug caused fewer bleeding incidents among patients with atrial fibrillation than the commonly prescribed apixaban, according to results from a head-to-head comparison of ...

The oral anticoagulant drug apixaban may offer a safer, more effective alternative to standard home heparin injections for patients taking extended prophylaxis (EP) to prevent blood-clot-related ...

NEW YORK, July 8 (Reuters) - An experimental anti-clotting medicine from Bristol-Myers Squibb Co. and Pfizer Inc. met its main effectiveness and safety goals in a mid-stage study, researchers said on ...

Factor XI inhibition was potentially the Goldilocks anticoagulant target with the promise of a reduction in thrombotic risk without a significant increase in bleeding. The early phase 2 data were ...

The appropriate duration of anticoagulation for venous thromboembolism (VTE) in patients who have a transient provoking factor (e.g., surgery, trauma, or immobility) and concomitant enduring risk ...

Hemophilia A is a genetic bleeding disorder caused by a deficiency in clotting factor VIII. Treatment focuses on managing bleeding episode symptoms with clotting factor replacement therapy, ...